Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).
Bonifácio LP, Ramacciotti E, Agati LB, Vilar FC, Silva ACTD, Louzada Júnior P, Fonseca BALD, Souza HCC, Oliveira CCC, Aguiar VCR, Quadros CAA, Dusilek C, Itinose K, Risson R, Ferreira LRR, Lopes RD, Kallas EG, Bellissimo-Rodrigues F. Bonifácio LP, et al. Among authors: agati lb. Rev Soc Bras Med Trop. 2023 Apr 14;56:e0565. doi: 10.1590/0037-8682-0565-2022. eCollection 2023. Rev Soc Bras Med Trop. 2023. PMID: 37075454 Free PMC article. Clinical Trial.
Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial.
Ramacciotti E, Ferreira U, Costa AJV, Raymundo SRO, Correa JA, Neto SG, Osvaldt AB, Agati L, Aguiar VCR, Davila R, Caltabiano TB, Magella FM, Volpiani GG, Castelli V Jr, Caffaro RA, DalAcqua LZ, Matheus WE, Sato DY, Russeff GJDS, de Souza DG, Pazetto LE, de Lima TAM, Colnago EMDS, Fugii EY, Mussalem JS, Assao VT, Toffoletto O, Rodrigues DG, Afiune JB, Araujo GR. Ramacciotti E, et al. Clin Appl Thromb Hemost. 2018 Nov;24(8):1208-1215. doi: 10.1177/1076029618786583. Epub 2018 Jul 18. Clin Appl Thromb Hemost. 2018. PMID: 30021463 Free PMC article. Clinical Trial.
Zika and Chikungunya Virus and Risk for Venous Thromboembolism.
Ramacciotti E, Agati LB, Aguiar VCR, Wolosker N, Guerra JC, de Almeida RP, Alves JC, Lopes RD, Wakefield TW, Comerota AJ, Walenga J, Fareed J. Ramacciotti E, et al. Among authors: agati lb. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029618821184. doi: 10.1177/1076029618821184. Clin Appl Thromb Hemost. 2019. PMID: 30808213 Free PMC article.
Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.
Biagioni RB, Lopes RD, Agati LB, Sacilotto R, Wolosker N, Sobreira ML, de Freitas Soares BL, Joviliano EE, Bernardi WH, Junior VC, Caffaro RA, Fioranelli A, Van Bellen B, Casella IB, Fidelis RJR, Flumignan RLG, Comerota AJ, Ramacciotti E. Biagioni RB, et al. Among authors: agati lb. Am Heart J. 2020 Sep;227:100-106. doi: 10.1016/j.ahj.2020.06.010. Epub 2020 Jun 23. Am Heart J. 2020. PMID: 32730905
Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial.
Ramacciotti E, Agati LB, Calderaro D, Volpiani GG, de Oliveira CCC, Aguiar VCR, Rodrigues E, Sobreira ML, Joviliano EE, Dusilek C, Itinose K, Dedivitis RA, Cortina AS, Sanches SMV, de Moraes NF, Tierno PFGMM, de Oliveira ALML, Tachibana A, Chate RC, Santos MVB, Cavalcante BBM, Moreira RCR, Chiann C, Tafur A, Spyropoulos AC, Lopes RD. Ramacciotti E, et al. Among authors: agati lb. Am Heart J. 2021 Dec;242:115-122. doi: 10.1016/j.ahj.2021.08.016. Epub 2021 Sep 1. Am Heart J. 2021. PMID: 34480880 Free PMC article.
Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial.
Ramacciotti E, Agati LB, Volpiani GG, Brito KF, Ribeiro CM, Aguiar VCR, Ramacciotti LS, Paganotti A, Pereira FM, Caffaro RA, Fioranelli A, Krakauer R, Rached HRS, Wolosker N, Anand SS, Eikelboom JW, Lopes RD. Ramacciotti E, et al. Among authors: agati lb. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296211073922. doi: 10.1177/10760296211073922. Clin Appl Thromb Hemost. 2022. PMID: 35043716 Free PMC article. Clinical Trial.
Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial : Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial).
Longo de Oliveira ALM, de Oliveira Pereira RF, Agati LB, Ribeiro CM, Kawamura Suguiura GY, Cioni CH, Bermudez M, Pirani MB, Caffaro RA, Castelli V Jr, Resende Aguiar VC, Volpiani GG, Paschoa A, Scarlatelli Macedo AV, de Barros E Silva PGM, de Campos Guerra JC, Fareed J, Lopes RD, Ramacciotti E. Longo de Oliveira ALM, et al. Among authors: agati lb. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221132556. doi: 10.1177/10760296221132556. Clin Appl Thromb Hemost. 2022. PMID: 36474344 Free PMC article. Clinical Trial.
Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study.
Carvalho de Oliveira CC, Agati LB, Ribeiro CM, Resende Aguiar VC, Caffaro RA, da Silva Santos M, Alves Fernandes RR, Alberto da Silva Magliano C, Tafur A, Spyropoulos AC, Lopes RD, Fareed J, Ramacciotti E. Carvalho de Oliveira CC, et al. Among authors: agati lb. Lancet Reg Health Am. 2023 Aug;24:100543. doi: 10.1016/j.lana.2023.100543. Epub 2023 Jun 23. Lancet Reg Health Am. 2023. PMID: 37366432 Free PMC article.
11 results